Suppr超能文献

新型注射装置提高自我给药体验:在银屑病患者中使用 risankizumab 的真实体验。

Improvement of self-administration experience with a new injection device: Real-life experience with risankizumab in patients with psoriasis.

机构信息

Unit of Dermatology, Villa Scassi Hospital, ASL3, Genoa, Italy.

Section of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy.

出版信息

Skin Res Technol. 2024 Aug;30(8):e13902. doi: 10.1111/srt.13902.

Abstract

BACKGROUND

Trypanophobia or "needle phobia" represents a potential hindrance to the effective management of chronic diseases whenever an injectable therapy might be required, especially in case of frequent administrations. Psoriasis, a chronic dermatologic disease, can be effectively treated with biologic drugs administered subcutaneously. Thankfully, anti-IL-23 drugs require few administrations per year and are available in prefilled pens that hide the needle, thus representing a convenient option in patients with trypanophobia.

METHODS

An observational multicentric study was conducted on patients with moderate-to-severe psoriasis who were treated with 75 mg × 2 risankizumab prefilled syringe therapy for more than 6 months and reported a loss of efficacy measured by the Psoriasis Area and Severity Index (PASI) from PASI 90 to PASI 75 attributed to a reduction of adherence due to trypanophobia. The patients were switched to 1 prefilled pen of risankizumab 150 mg and asked to fill out the Self-Injection Assessment Questionnaire (SIAQ) before and after the injection at week 0 and at the following administration after 12 weeks. Subjects scored each item of the SIAQ on a 5-point scale, scores were later transformed from 0 (worst experience) to 10 (best experience).

RESULTS

Twenty-two patients were enrolled. The mean SIAQ predose domain scores were 5.5 for feelings about injection, 6.2 for self-confidence, and 6.4 for satisfaction with self-injection. After dose scores were higher (> 8.5) for each of the six domains at Week 0 and even higher after 12 weeks (> 9.0).

CONCLUSIONS

User-friendly devices, such as prefilled pens, and a lower number of injections improved patient satisfaction in a group of patients with psoriasis on treatment with biologic drugs. We believe that treatment adherence could be positively influenced by such changes in the way of administration of a biologic treatment.

摘要

背景

恐针症(又名“针恐惧症”)是一种潜在障碍,可能会影响慢性疾病的有效管理,尤其是在需要注射治疗且需要频繁注射的情况下。银屑病是一种慢性皮肤病,可以通过皮下注射生物药物进行有效治疗。值得庆幸的是,抗白细胞介素-23 药物每年只需注射几次,并且有预充式注射器可供使用,这种注射器隐藏了针头,对于有恐针症的患者来说是一种方便的选择。

方法

对接受 75mg×2 利纳西单抗预装注射器治疗超过 6 个月且因恐针症导致依从性降低而导致疗效丧失(根据银屑病面积和严重程度指数[PASI]从 PASI90 降至 PASI75 评估)的中重度银屑病患者进行了一项观察性多中心研究。这些患者改用 1 支利纳西单抗 150mg 预装笔,并在第 0 周和第 12 周后的下一次给药前和给药后填写自我注射评估问卷(SIAQ)。受试者对 SIAQ 的每个条目进行 5 分制评分,评分随后从 0(最差体验)转换为 10(最佳体验)。

结果

共纳入 22 例患者。SIAQ 预注射剂量域评分的平均分数分别为注射感受 5.5 分、自我信心 6.2 分和自我注射满意度 6.4 分。第 0 周时,每个剂量域的 SIAQ 评分均高于 8.5(>8.5),第 12 周后甚至更高(>9.0)。

结论

在接受生物药物治疗的银屑病患者中,使用预充式笔等易于使用的装置和减少注射次数可提高患者满意度。我们认为,通过改变生物治疗的给药方式,可以积极影响治疗依从性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb7/11333944/d720b41da2d4/SRT-30-e13902-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验